Achilles therapeutics reports second quarter 2022 financial results and recent business highlights

- additional clinical data from the ongoing phase i/iia trials in advanced nsclc (chiron) and melanoma (thetis) expected to be available in q4 2022 -

ACHL Ratings Summary

ACHL Quant Ranking